Preoperative speech rehabilitation for patients with drug-resistant temporal epilepsy

Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy

Not applicable Interventional Assistance Publique Hopitaux De Marseille · NCT05609084

This study is testing a speech therapy program for people with drug-resistant temporal lobe epilepsy to see if it can help improve their thinking and memory skills before they have surgery.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment214 (estimated)
Ages16 Years and up
SexAll
SponsorAssistance Publique Hopitaux De Marseille Academic / other
Locations12 sites (Bordeaux and 11 other locations)
Trial IDNCT05609084 on ClinicalTrials.gov

What this trial studies

This study focuses on patients with drug-resistant temporal lobe epilepsy who are candidates for neurosurgery. It aims to implement a specific speech rehabilitation program designed to improve cognitive functions, particularly lexical access and verbal memory, prior to surgical intervention. The approach is based on cognitive theories and models of neural plasticity, with the goal of enhancing cognitive reserve and potentially mitigating postoperative cognitive difficulties. Participants will undergo speech therapy assessments and interventions tailored to their needs.

Who should consider this trial

Good fit: Ideal candidates are patients aged 16 and older with drug-resistant temporal lobe epilepsy involving the language-dominant hemisphere.

Not a fit: Patients whose epilepsy is not drug-resistant or who do not have a language-dominant hemisphere involvement may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve cognitive outcomes and quality of life for patients undergoing surgery for temporal lobe epilepsy.

How similar studies have performed: While there is limited research on preoperative cognitive rehabilitation in this specific context, similar approaches in other neurological conditions have shown promise.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient 16 years of age and older,
2. Patient whose epileptogenic area involves the temporal structures of the hemisphere specialized for language,
3. Patient whose hemispheric specialization for language is known
4. Patient willing to undergo resective surgery such as anterior temporal lobectomy or resection in the temporal lobe involving the hippocampus and/or the baso-temporal language area and whose planned surgery date is compatible with the performance of the study,
5. Patient with a known NTB score
6. Patient who has signed an informed consent or patient whose parents or legal guardians have signed the informed consent (or a single parent or legal guardian if applicable)
7. Patient whose first language is French (1st language learned by the patient),
8. Patient declaring to be familiar with the use of a computer and having access to an internet connection from home
9. Patient affiliated or benefiting from a social security system.

Exclusion Criteria:

1. Patient with a speech disorder that may impair intelligibility and compromise the use of the interface;
2. Patient with an uncorrected hearing impairment,
3. Patients with a total intelligence quotient (IQ) \<70 (assessed in the context of care, in the year preceding the surgical procedure)
4. Patients who are pregnant, nursing, deprived of liberty, under guardianship or curatorship.

Where this trial is running

Bordeaux and 11 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions EpilepsyAnomiaTemporal Lobe Epilepsy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.